Related Experiment Videos
[Pathogenesis of mental impairment in trisomy 21]
1Centre de Recherches Claude-Bernard, Génétique Humaine et Maladies de l'Intelligence, Institut de Progenèse, Paris, France.
Abstract:
Short of discovering how to silence selectively one of the 3 chromosomes 21, no rational medication can be envisaged before pathogenesis has been unraveled, at least partially. A biochemical scheme of impairment of mental efficiency is presented, and the possible deleterious effects of a given gene overdose are discussed. Cu/Zn SOD, cystathionine beta synthase, S 100 beta protein, phosphofructokinase, purine synthesis and adenosine pharmacology, thyroid disturbance, and elevated TSH with low rT3 as well as biopterin metabolism interferences are reviewed. These metabolic paths are tightly related by their effects, just as if synteny was in some way related to biochemical cooperation or mutual regulation. Experiments in vitro have demonstrated a peculiar sensitivity of trisomic 21 lymphocytes to methotrexate, and systematic research of special sensitivities has begun. Clinical observations and relevant statistical methods allow study of the speed of mental development under various medications. The interest of regulating thyroid metabolism, when needed, is exemplified. Re-equilibration of monocarbon metabolism is discussed and the seemingly favourable effect of folinic acid medication in pseudo Alzheimer complication is presented.
Insights
Understanding Down syndrome pathogenesis is key to developing effective treatments. Research explores biochemical pathways and potential drug interventions for mental efficiency and developmental speed in trisomy 21.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Context:
- Down syndrome (trisomy 21) presents complex biochemical alterations impacting mental efficiency.
- Current treatment strategies are limited without a full understanding of the pathogenesis.
- Gene dosage effects and metabolic pathway interferences are central to Down syndrome research.
Purpose:
- To present a biochemical scheme of mental efficiency impairment in trisomy 21.
- To discuss the impact of gene overdose on metabolic pathways.
- To review potential therapeutic targets and interventions.
Summary:
- This study outlines biochemical pathways affected in Down syndrome, including Cu/Zn SOD, cystathionine beta synthase, and thyroid hormone metabolism.
- It highlights the sensitivity of trisomic cells to methotrexate and explores the potential of medications like folinic acid.
- The research connects metabolic interferences, suggesting a biochemical cooperation possibly linked to synteny.
Impact:
- Provides a framework for understanding Down syndrome's biochemical basis, guiding future drug discovery.
- Identifies specific metabolic pathways and sensitivities that could be targeted for therapeutic intervention.
- Suggests novel approaches for improving mental development and addressing complications in individuals with Down syndrome.